These results indicate that metformin can activate AMPK-ATF1-M2-like pathways in macrophages to inhibit AS in hyperlipidemia mice, and support the clinical study of metformin in people without DM but with high risk of AS (115, 116). This evidence concerns the gene PRKAA1 and diabetes mellitus.